<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2492">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128721</url>
  </required_header>
  <id_info>
    <org_study_id>NO-B041</org_study_id>
    <nct_id>NCT05128721</nct_id>
  </id_info>
  <brief_title>Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Vaccine Against COVID-19 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Centre, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Centre, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase 1 study, the inactivated virus vaccine National Research Centre (NRC)&#xD;
      Vaccine-101 (VACC-101) will be investigated for its safety and immunogenicity in healthy&#xD;
      volunteers with the aim of providing effective and safe protection against COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, Randomized, Open-Labeled Clinical trial. Eligible volunteers will be&#xD;
      randomized in a 1:1:1 allocation ratio, into one of the three study arms using the&#xD;
      Interactive Web Response Technology (IWRS).&#xD;
&#xD;
      Unscheduled visits can occur at any time during the study period outside the initially&#xD;
      planned study visits, all the extra visits will be documented in the subjects' files.&#xD;
      Volunteers will be randomized into one of the following arms to receive different doses of&#xD;
      the Inactivated&#xD;
&#xD;
      SARS-COV-2 Vaccine &quot;NRC-VACC-101&quot; as an intramuscular (IM) Injection or Placebo:&#xD;
&#xD;
      Arm One:&#xD;
&#xD;
      Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.&#xD;
&#xD;
      Arm Two:&#xD;
&#xD;
      Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.&#xD;
&#xD;
      Arm Three (Control arm):&#xD;
&#xD;
      Volunteers will receive two IM doses of the placebo, 28 days apart. The first 9 subjects will&#xD;
      be initially vaccinated with their first dose, as per their assigned study arm determined by&#xD;
      the randomization procedures and will be followed up until day 14 (visit 03). At this point&#xD;
      in the study, the Data Safety and Monitoring Board (DSMB) will review safety data before&#xD;
      proceeding with vaccinating the rest of the recruited subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 14, 2021</start_date>
  <completion_date type="Anticipated">May 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 23, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Randomized, Open-label, Phase 1 Clinical trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety of NRC-VACC-101 Vaccine</measure>
    <time_frame>Follow up for any solicited adverse event(AE) reported within 7 days</time_frame>
    <description>To evaluate the safety of the proposed regimens of NRC-VACC-101</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The tolerability of NRC-VACC-101 Vaccine</measure>
    <time_frame>Follow up for any AE within 28 days of each dose</time_frame>
    <description>To evaluate the tolerability of the proposed regimens of NRC-VACC-101 Vaccine in the healthy population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The seroconversion rate of neutralizing antibodies</measure>
    <time_frame>The evaluation of the antibody will be measured up to one month of each dose</time_frame>
    <description>To evaluate the seroconversion rate of neutralizing antibodies resulting from the NRC-VACC-101 Vaccine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To recommend the dose level of NRC-VACC-101 Vaccine for the phase II trial.</measure>
    <time_frame>The evaluation of the Microneutralization Assay will be assessed up to one month of each dose</time_frame>
    <description>The evaluation of the Microneutralization Assay curve will give an overview of the dose possible suggested dose of NRC-VACC-101 Vaccine for the phase II trial</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>COVID-19</condition>
  <condition>Vaccine Reaction</condition>
  <condition>Vaccine Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>NRC-VACC-101 vaccine 3 microgram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers will receive two IM doses of the vaccine, concentrations of 3 mcg, 28 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NRC-VACC-101 vaccine 6 microgram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers will receive two IM doses of the vaccine, concentrations of 6 mcg, 28 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volunteers will receive two IM doses of the placebo (excipients only), 28 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Covi Vax</intervention_name>
    <description>Inactivated SARS-COV-2 Vaccine/alum adjuvant preparation in addition to excipients (NRC-VACC- 101) administered as an IM Injection. NRC-VACC-101 is provided as a single dose of inactivated vaccine of opaque white liquid free from visible particles filled in injection vial (2R) glass vials. Each Dose of Covi Vax Vaccine contains 6 mcg antigen of A human coronavirus (hCoV)-19/Egypt/NRC-03/2020 SARS-CoV-2 strain.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>NRC-VACC-101 vaccine 3 microgram</arm_group_label>
    <arm_group_label>NRC-VACC-101 vaccine 6 microgram</arm_group_label>
    <other_name>NRC-VACC-101 vaccine</other_name>
    <other_name>Egyptian Inactivated SARS-CoV-2 Vaccine</other_name>
    <other_name>NRC Inactivated SARS-CoV-2 Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults with age 18 to 50 years.&#xD;
&#xD;
          2. Willingness.&#xD;
&#xD;
          3. For married females of childbearing age: Willingness to practice continuous effective&#xD;
             contraception for one year from the start of the study.&#xD;
&#xD;
          4. Agreement to refrain from blood donation during the study.&#xD;
&#xD;
          5. Body temperature is within the normal range (36.5 - 37.5Â°C).&#xD;
&#xD;
          6. General good health as established by medical history, physical and laboratory&#xD;
             examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or lactation.&#xD;
&#xD;
          2. Inability to provide informed consent.&#xD;
&#xD;
          3. Recent receipt of any vaccination within 30 days prior to baseline.&#xD;
&#xD;
          4. Planning to receive any vaccination during the course of the study.&#xD;
&#xD;
          5. Prior receipt of Adenovirus vaccine, or any other Coronavirus vaccine.&#xD;
&#xD;
          6. Recent receipt of any immunoglobulin within 90 days prior to baseline.&#xD;
&#xD;
          7. Recent receipt of any blood product within 90 days prior to baseline.&#xD;
&#xD;
          8. Volunteers who are immunosuppressed or receiving immunosuppressive medications,&#xD;
             including:&#xD;
&#xD;
             HIV infection, asplenia, recurrent severe infections, and the use of immunosuppressive&#xD;
             medications within the past 6 months, except for topical steroids or short-term oral&#xD;
             steroids (course lasting &lt; 14 days).&#xD;
&#xD;
          9. Currently taking any product (investigational or off-label) for prevention of COVID-19&#xD;
             disease.&#xD;
&#xD;
         10. Having any autoimmune disease.&#xD;
&#xD;
         11. History of allergic reactions for any of the vaccine components.&#xD;
&#xD;
         12. History of angioedema.&#xD;
&#xD;
         13. History of anaphylaxis.&#xD;
&#xD;
         14. History of cancer.&#xD;
&#xD;
         15. History of serious psychiatric conditions that are likely to affect participation in&#xD;
             the study.&#xD;
&#xD;
         16. Having bleeding disorders.&#xD;
&#xD;
         17. Having chronic respiratory diseases.&#xD;
&#xD;
         18. Having chronic cardiovascular disease, gastrointestinal disease, liver disease, renal&#xD;
             disease, endocrine disorders, and neurological illness.&#xD;
&#xD;
         19. Volunteers with BMI â¥ 40 Kg/m2 or â¤ 18 Kg/m2.&#xD;
&#xD;
         20. Current alcohol abuse.&#xD;
&#xD;
         21. Drug abuse within 5 years prior to baseline.&#xD;
&#xD;
         22. History of laboratory-confirmed COVID-19 or seropositivity for SARS-CoV-2 or positive&#xD;
             serum immunoglobulin M (IgM) and immunoglobulin G (IgG) to the SARS CoV-2 or abnormal&#xD;
             chest CT-Scan (COVID-19 image) or positive pharyngeal/sputum swabs for SARS-CoV-2.&#xD;
&#xD;
         23. Participation in other studies involving study intervention within 28 days prior to&#xD;
             study entry and/or during study participation.&#xD;
&#xD;
         24. High-risk population (volunteers who work in front-line health facilities or were in&#xD;
             close contact with confirmed COVID-19 cases).&#xD;
&#xD;
         25. Living in the same household as anyone at high risk of severe COVID-19.&#xD;
&#xD;
         26. Any condition, according to the judgment of the investigator, that would interfere&#xD;
             with the subject's ability to comply with all study requirements or that would place&#xD;
             the subject at unacceptable risk by his/her participation in the study or impair the&#xD;
             interpretation of the study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Azmy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Research and Clinical Studies Institute National Research Centre, Dokki, Giza, Egypt.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osama Azmy, MD</last_name>
    <phone>+201223103084</phone>
    <email>osamaazmy@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Trial Unit Clinical Trial Unit National Research Centre, MD</last_name>
    <phone>+20237623009</phone>
    <email>ctu.mrce@nrc.sci.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Research Centre of Excellence National Research Centre</name>
      <address>
        <city>Cairo</city>
        <state>Giza</state>
        <zip>12622</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Osama Azmy, MD</last_name>
      <phone>+201223103084</phone>
      <email>osamaazmy@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Inactivated SARS-CoV-2 Vaccine</keyword>
  <keyword>NRC-VACC-101</keyword>
  <keyword>Vaccine Safety</keyword>
  <keyword>Vaccine Tolerability</keyword>
  <keyword>Vaccine Immunogenicity</keyword>
  <keyword>Covi Vax</keyword>
  <keyword>Egyptian Inactivated SARS-CoV-2 Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared upon individual request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>About one year after completion of the trial</ipd_time_frame>
    <ipd_access_criteria>Data will be shared upon individual request by contacting the sponsor of the trial.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

